The prospective, double-blind, randomized controlled trial (RCT) enrolled 244 patients to evaluate the Butterfly Prostatic Retraction Device, a minimally invasive, reversible implant that mechanically ...

UCHealth hospital uses BPH AI to guide aquablation, improving precision and preserving sexual function in prostate treatment.

Butterfly Medical announced that it completed the final 12-month follow-up for all patients in a study of its prostatic ...

Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function The Mount Sinai Hospital is ranked ...

Treatment with vibegron reduced the average number of micturition episodes per day and the average number of daily urgency episodes compared with placebo. The Food and Drug Administration (FDA) has ...

Teleflex Incorporated announced the presentation of multiple clinical studies at the 2025 American Urological Association Annual Meeting in Las Vegas, highlighting advancements in treatments for ...

Benign prostatic hyperplasia (BPH) is one of the most common urologic conditions affecting men as they age, with nearly 50% of men over 50 experiencing symptoms. Despite its prevalence, treatment ...

Designed with the patient experience in mind, the Zenflow Spring Implant and Delivery System opens the urethra while preserving natural anatomy through a proprietary small spring-like implant. The ...

Benign prostate hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland, which is generally the shape and size ...

A regulatory decision is expected in the third quarter of 2024. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for vibegron for the treatment of men ...